So far, more than 100 different cannabinoids have been identified, and there is a growing body of evidence supporting the clinical benefits of this class of compounds in treating the symptoms of a wide variety of chronic health conditions
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of endocannabinoid system targeting drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
§ A detailed assessment of the current market landscape of drug developers engaged in the development of endocannabinoid system targeted therapeutics.
§ Detailed profiles of developers of endocannabinoid system targeted therapeutics (shortlisted on the basis of the number of development programs).
§ An in-depth analysis of nearly 600 grants that have been awarded to research institutes engaged in endocannabinoid system targeted therapeutics projects.
§ An analysis of the partnerships that have been established in this domain, in the recent past.
§ A detailed analysis of the various mergers and acquisitions that have taken place in this domain, between 2016-2020
§ An insightful chessboard analysis highlighting the most popular drug development strategies / paths adopted by various drug developers in the domain of endocannabinoid system targeted therapeutics.
§ A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
§ Target Disease Indication
§ Genetic Disorders
§ Neurological Indications
- Route of Administration
- Key Geographies
§ North America
§ Asia-Pacific and the Rest of the World
Key companies covered in the report
§ GW Pharmaceuticals
§ Corbus Pharmaceuticals
§ Tetra Bio-Pharma
§ Botanix Pharmaceuticals
§ Kalytera Therapeutics
§ Therapix Biosciences
§ Echo Pharmaceuticals
§ GB Sciences
For more information please click on the following link:
Other Recent Offerings
1. Neoantigen Targeted Therapies Market, 2019-2030
2. Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics
3. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
4. Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030
+1 (415) 800 3415
+44 (122) 391 1091
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at firstname.lastname@example.org
Roots Analysis Private Limited
+1 (415) 800 3415